Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLI…
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLI…
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLI…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company's medical device AnaConDa, for the administration of volatile anesthetics for sedation of mechanically ventilated intensive care patients, has received approval for use…
Regulatory
Strategic partnership in Asia and continued strong growth
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a distribution agreement with the Indian distributor Hansraj Nayyar Medical. Sales will commence in the fall and a registration process will start in parallel. Hansraj Nayyar has committ…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the recipients of the Sedana Medical Research Foundation (SMRF) grant 2019. Three research projects will receive funding from SMRF 2019 covering the area of inhaled sedation in the inten…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a 10-year exclusive distribution agreement with the Chinese distributor Kyuan Xinhai Medical, a subsidiary of partly state-owned Shanghai Pharma, the second largest life science company…
Regulatory
Sedana Medical AB (publ) (the "Company") held its annual general meeting on 28 May 2019 in Stockholm. The meeting resolved in accordance with all of the board of directors' and nomination committee's resolution proposals. Complete information on each…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the first patient in Japan has been treated with AnaConDa and that the registration work for IsoConDa in Japan has been initiated. The Japanese market potential is estimated at EUR…
Regulatory
Clear regulatory pathway to approval in EU and USA
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announce that its Annual Report for 2018 has been published and is available on www.sedanamedical.com under Investors.
Regulatory
Sedana Medical AB (publ) hereby convenes the Annual General Meeting 2018. The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting on Tuesday 28 May 2019 at 4 p.m. (CEST) at Eri…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the US Food and Drug Administration (FDA) during a pre-IND meeting is positive about the combination registration of IsoConDa and AnaConDa in the US. Sedana Medical now has a clear…
Regulatory
“The fourth quarter and 2018 have been eventful, but in many ways, it is only the start of our journey. I look forward with excitement to the future.” - Christer Ahlberg, President and CEO Sedana Medical (publ)
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the results of the interim analysis for the company's pivotal phase III study aimed at getting the candidate drug IsoConDa (isoflurane) approved for inhalation sedation in intensive care…
Regulatory
Sedana Medical AB (publ) announce today that the year-end report for 2018 will be released Tuesday 12th of March 2019 at 07.00 CET instead of 21st of March.
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the establishment of the Sedana Medical Research Foundation, creating a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pati…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces the company has been approved for its planned pediatric study from the Pediatric Committee of EMA, European Medicines Agency, (PDCO).
Regulatory
In the previously announced press release the following text was included: This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure…